Medmain, a Japanese AI pathology startup, has successfully raised $3.3M to enhance its digital pathology services and expand internationally amid increasing demand.

Medmain Inc. has initiated the PidPort Personal Plan for private users, offering a 3-month free trial for new subscribers to enhance pathology image storage.

The money will support the development of the firm's PidPort system for storage, viewing, sharing, and analysis of digital images of pathology slides.

FUKUOKA, Japan, May 8, 2025 /PRNewswire/ -- Medmain Inc., a Japanese medtech startup that offers PidPort, an AI-powered cloud system to assist in digital pathology, is pleased to announce that it has raised 3.3 million USD through a third-party allotment of shares, with One Capital as the lead inves...

Medmain Inc. has successfully developed an AI system to automatically measure Ki-67 positive cell rates in digital pathology images, as detailed in Diagnostics journal.

Medmain Inc. has successfully obtained a patent for an AI-driven system designed to streamline the creation of pathology reports, significantly enhancing diagnostic accuracy and reducing workload.

Medmain's digital pathology AI system, PidPort, has started its trials at Ha Dong General Hospital in Hanoi, Vietnam, enhancing diagnostic accuracy.

Medmain Inc. and SMC Medical Tourism Japan have signed a partnership to promote AI-driven pathology diagnostics in Vietnam, enhancing medical cooperation.

Medmain, a leading tech company, has signed an MOU with various Vietnamese hospitals to implement AI-driven digital pathology solutions, aiming to revolutionize healthcare.

Medmain has successfully raised ¥470 million, bringing its total funding to ¥2.5 billion, aiming to enhance its pathology AI platform and global outreach.